Cullinan Management, Inc.
News
Cullinan Therapeutics to Participate in Upcoming Investor Conferences
Globe Newswire CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; Cullinan ), a biopharmaceutical company focused on developing modality-agnostic targeted therapies...\n more…
CGEM Stock Earnings: Cullinan Therapeutics Misses EPS for Q2 2024
InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nCGEM stock results show that Cullinan Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.\nThe post...\n more…
Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
Globe Newswire Investigational New Drug (IND) application for CLN-978 in systemic lupus erythematosus (SLE) remains on track to be filed in third quarter of 2024 Company to pursue rheumatoid arthritis (RA) as...\n more…
Institutional owners may ignore Cullinan Therapeutics, Inc.'s (NASDAQ:CGEM) recent US$105m market cap decline as longer-term profits stay in the green
Simply Wall St Key Insights Given the large stake in the stock by institutions, Cullinan Therapeutics' stock price might be vulnerable...\n more…
Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib
Globe Newswire Objective response rate of 39% with manageable safety profile in patients with non-small cell lung cancer (NSCLC) harboring EGFR Exon 20 insertion mutations treated with zipalertinib who had...\n more…
Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit
Globe Newswire CAMBRIDGE, Mass., May 24, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today...\n more…